• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫介导疾病中建立耐受的方法。

Approaches to Establishing Tolerance in Immune Mediated Diseases.

机构信息

Immune Tolerance Network, University of California San Francisco, San Francisco, CA, United States.

Immune Tolerance Network, Duke University, Durham, NC, United States.

出版信息

Front Immunol. 2021 Sep 20;12:744804. doi: 10.3389/fimmu.2021.744804. eCollection 2021.

DOI:10.3389/fimmu.2021.744804
PMID:34616405
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8488342/
Abstract

The development of rational approaches to restore immune tolerance requires an iterative approach that builds on past success and utilizes new mechanistic insights into immune-mediated pathologies. This article will review concepts that have evolved from the clinical trial experience of the Immune Tolerance Network, with an emphasis on lessons learned from the innovative mechanistic studies conducted for these trials and new strategies under development for induction of tolerance.

摘要

理性的免疫耐受恢复方法的发展需要一种迭代方法,该方法建立在过去的成功基础上,并利用对免疫介导的病理的新机制见解。本文将回顾从免疫耐受网络临床试验经验中发展而来的概念,重点介绍这些试验中进行的创新性机制研究的经验教训,以及正在开发的诱导耐受的新策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b8/8488342/c5fd1bde4712/fimmu-12-744804-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b8/8488342/2d63f75ead21/fimmu-12-744804-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b8/8488342/c5fd1bde4712/fimmu-12-744804-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b8/8488342/2d63f75ead21/fimmu-12-744804-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b8/8488342/c5fd1bde4712/fimmu-12-744804-g002.jpg

相似文献

1
Approaches to Establishing Tolerance in Immune Mediated Diseases.免疫介导疾病中建立耐受的方法。
Front Immunol. 2021 Sep 20;12:744804. doi: 10.3389/fimmu.2021.744804. eCollection 2021.
2
Challenges in the pursuit of immune tolerance.免疫耐受的挑战。
Immunol Rev. 2011 May;241(1):49-62. doi: 10.1111/j.1600-065X.2011.01003.x.
3
The Immune Tolerance Network at 10 years: tolerance research at the bedside.免疫耐受网络成立 10 年:临床的耐受研究。
Nat Rev Immunol. 2010 Nov;10(11):797-803. doi: 10.1038/nri2869.
4
Immunologic tolerance for immune system-mediated diseases.免疫系统介导疾病的免疫耐受。
J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):362-70. doi: 10.1016/s0091-6749(99)70457-4.
5
Oral tolerance: can we make it work?口服耐受:我们能使其发挥作用吗?
Hum Immunol. 2009 Oct;70(10):768-76. doi: 10.1016/j.humimm.2009.06.018. Epub 2009 Jun 25.
6
Exploiting apoptosis for therapeutic tolerance induction.利用细胞凋亡诱导治疗性耐受。
J Immunol. 2013 Dec 1;191(11):5341-6. doi: 10.4049/jimmunol.1302070.
7
[Deviations in the immune response. I. Immunologic tolerance].[免疫反应的偏差。I. 免疫耐受性]
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol. 1989 Jul-Sep;34(3):193-8.
8
Neuroimmunomodulation by nutrition in stress situations.应激状态下营养对神经免疫的调节作用。
Neuroimmunomodulation. 2008;15(3):165-9. doi: 10.1159/000153420. Epub 2008 Sep 9.
9
Clinical trials of transplant tolerance: slow but steady progress.移植耐受的临床试验:进展缓慢但稳步推进。
Am J Transplant. 2003 Jul;3(7):794-803. doi: 10.1046/j.1600-6135.2003.0154.x.
10
Applying embryo-derived immune tolerance to the treatment of immune disorders.将胚胎来源的免疫耐受性应用于免疫紊乱的治疗。
Ann N Y Acad Sci. 2007 Sep;1110:602-18. doi: 10.1196/annals.1423.064.

引用本文的文献

1
Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway.视神经脊髓炎谱系障碍(NMOSD)和复发性髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)中耐受性因子可溶性CD83(sCD83)降低:一种潜在的新治疗途径。
Front Immunol. 2025 Jul 24;16:1620069. doi: 10.3389/fimmu.2025.1620069. eCollection 2025.
2
Induction of immune tolerance in NMOSD and MOGAD.在视神经脊髓炎谱系障碍(NMOSD)和髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)中诱导免疫耐受。
Ther Adv Neurol Disord. 2025 Aug 1;18:17562864251357393. doi: 10.1177/17562864251357393. eCollection 2025.
3
Receptor-Mediated SPION Labeling of CD4 T Cells for Longitudinal MRI Tracking of Distribution Following Systemic Injection in Mouse.

本文引用的文献

1
Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome.病例报告:达雷妥尤单抗靶向浆细胞重置抗磷脂综合征的体液免疫反应。
Front Immunol. 2021 Apr 12;12:667515. doi: 10.3389/fimmu.2021.667515. eCollection 2021.
2
The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease.达雷妥尤单抗在冷凝集素病患者中的免疫调节作用和临床疗效。
Front Immunol. 2021 Mar 1;12:649441. doi: 10.3389/fimmu.2021.649441. eCollection 2021.
3
Evolution of epitope-specific IgE and IgG antibodies in children enrolled in the LEAP trial.
用于小鼠全身注射后分布的纵向MRI追踪的CD4 T细胞的受体介导的超顺磁性氧化铁标记
Nanomaterials (Basel). 2025 Jul 10;15(14):1068. doi: 10.3390/nano15141068.
4
Exploring the Immunological Role of the Microbial Composition of the Appendix and the Associated Risks of Appendectomies.探索阑尾微生物组成的免疫作用及阑尾切除术的相关风险。
J Pers Med. 2025 Mar 14;15(3):112. doi: 10.3390/jpm15030112.
5
Immunohaemostasis and the significance of immune reactions in the regulation of blood coagulation.免疫止血及免疫反应在血液凝固调节中的意义。
Eur J Microbiol Immunol (Bp). 2024 Dec 4;14(4):392-404. doi: 10.1556/1886.2024.00107. Print 2024 Dec 18.
6
Engineered Immune Constructs Alter Antigen-Specific Immune Tolerance and Confer Durable Protection in Myelin-Driven Autoimmunity.工程化免疫构建体改变抗原特异性免疫耐受并在髓鞘驱动的自身免疫中提供持久保护。
ACS Nano. 2024 Nov 19;18(46):31780-31793. doi: 10.1021/acsnano.4c06667. Epub 2024 Nov 9.
7
Injectable Genetic Engineering Hydrogel for Promoting Spatial Tolerance of Transplanted Kidney in Situ.用于促进原位移植肾空间耐受性的可注射基因工程水凝胶
Adv Sci (Weinh). 2024 Dec;11(48):e2408631. doi: 10.1002/advs.202408631. Epub 2024 Nov 5.
8
The Usefulness of Thyroid Antibodies in the Diagnostic Approach to Autoimmune Thyroid Disease.甲状腺抗体在自身免疫性甲状腺疾病诊断方法中的应用价值
Antibodies (Basel). 2023 Jul 22;12(3):48. doi: 10.3390/antib12030048.
9
The Role of Viral Infections in the Onset of Autoimmune Diseases.病毒感染在自身免疫性疾病发病中的作用。
Viruses. 2023 Mar 18;15(3):782. doi: 10.3390/v15030782.
10
Synergistic targeting of immunologic pathways to empower durable tolerance therapies.协同靶向免疫途径以增强持久耐受疗法。
Front Immunol. 2022 Sep 2;13:962177. doi: 10.3389/fimmu.2022.962177. eCollection 2022.
在 LEAP 试验中入组的儿童中表位特异性 IgE 和 IgG 抗体的演变。
J Allergy Clin Immunol. 2021 Sep;148(3):835-842. doi: 10.1016/j.jaci.2021.01.030. Epub 2021 Feb 13.
4
Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.在接受阿法赛特治疗的1型糖尿病受试者中,与C肽保存相关的耗竭样CD8 + T细胞表型。
JCI Insight. 2021 Feb 8;6(3):142680. doi: 10.1172/jci.insight.142680.
5
Delivery mode and gut microbial changes correlate with an increased risk of childhood asthma.分娩方式和肠道微生物变化与儿童哮喘风险增加相关。
Sci Transl Med. 2020 Nov 11;12(569). doi: 10.1126/scitranslmed.aax9929.
6
Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.活体供肾移植受者中调节性T细胞疗法的可行性、长期安全性及免疫监测
Am J Transplant. 2021 Apr;21(4):1603-1611. doi: 10.1111/ajt.16395. Epub 2021 Feb 2.
7
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.达雷妥尤单抗治疗难治性系统性红斑狼疮的 CD38 靶点。
N Engl J Med. 2020 Sep 17;383(12):1149-1155. doi: 10.1056/NEJMoa2023325.
8
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.利妥昔单抗联合环磷酰胺序贯贝利尤单抗治疗狼疮肾炎的 II 期随机临床试验。
Arthritis Rheumatol. 2021 Jan;73(1):121-131. doi: 10.1002/art.41466. Epub 2020 Dec 1.
9
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.肾移植中的调节性细胞治疗(ONE 研究):七个非随机、单臂、1/2A 期的临床试验的协调设计和分析。
Lancet. 2020 May 23;395(10237):1627-1639. doi: 10.1016/S0140-6736(20)30167-7.
10
Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance.高风险哮喘新生儿粪便中 12,13-二去氢-11-羟基前列腺素 F2α 浓度升高是由肠道细菌产生的,并阻碍免疫耐受。
Nat Microbiol. 2019 Nov;4(11):1851-1861. doi: 10.1038/s41564-019-0498-2. Epub 2019 Jul 22.